The effect of including C-reactive protein in cardiovascular risk prediction models for women

Annals of Internal Medicine

Volumn 145, Issue 1, 2006, Pages 21-29

  Cook, Nancy R ^a   Buring, Julie E ^a   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; LIPID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; WOMEN'S HEALTH; AGE; BLOOD; CARDIOVASCULAR DISEASE; METABOLISM; METHODOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SMOKING; UNITED STATES;

AGE FACTORS; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SMOKING; UNITED STATES;

EID: 33745933659     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-145-1-200607040-00128     Document Type: Article

References (47)

1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
3. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-7.
4. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109:IV6-19.
5. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904.
6. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891-7.
7. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.
8. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-65.
9. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109:1349-53.
10. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837-42.
11. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
12. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-610.
13. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109:2818-25.
14. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation. 2005;112: 25-31.
15. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326-33.
16. Laaksonen DE, Niskanen L, Nisskanen K, Punnonen K, Tuomainen TP, Salonen JT. C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. Eur Heart J. 2005;26:1783-9.
17. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-7.
18. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acutephase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51: 1131-7.
19. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-34.
20. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391-7.
21. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
22. Grundy SM. The changing face of cardiovascular risk [Editorial]. J Am Coll Cardiol. 2005;46:173-5.
23. Buring JE, Hennekens CH. The Women's Health Study: summary of the study design. Journal of Myocardial Ischemia. 1992;4:27-9.
24. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med. 2000;9:19-27.
25. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304.
26. Hainline A, Karon J, Lippel K, eds. Manual of Laboratory Operations, Lipid Research Clinics Program, and Lipid and Lipoprotein Analysis. 2nd ed. Bethesda, MD: Department of Health and Human Services; 1982.
27. Cox DR. Regression models and life tables (with discussion). Journal of the Royal Statistical Society B. 1972;34:187-220.
28. Harrell FE Jr. Regression Modeling Strategies. New York: Springer; 2001.
29. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference and Prediction. New York: Springer-Verlag; 2001.
30. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
31. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman & Hall; 1993.
32. Burnham KP, Anderson DR. Model Selection and Inference: A Practical Information-Theoretic Approach. New York: Springer-Verlag; 1998.
33. Nagelkerke NJ. A note on a general definition of the coefficient of determination. Biomka. 1991;78:691-2.
34. Ash A, Shwartz M. R2: a useful measure of model performance when predicting a dichotomous outcome. Stat Med. 1999;18:375-84.
35. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med. 2004;23:723-48.
36. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 1997;16:965-80.
37. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: Wiley; 1981.
38. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104:1863-7.
39. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med. 2004;23:1631-60.
40. Gail MH, Pfeiffer RM. On criteria for evaluating models of absolute risk. Biostatistics. 2005;6:227-39.
41. Moons KG, Harrell FE. Sensitivity and specificity should be de-emphasized in diagnostic accuracy studies. Acad Radiol. 2003;10:670-2.
42. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839-44.
43. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-65.
44. Kent SM, Taylor AJ. Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dl and usefulness of C-reactive protein in patient selection. Am J Cardiol. 2003;92:1224-7.
45. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-8.
46. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
47. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis. 2005.